Therapeutic Applications & Evidence-Based Benefits of MOTS-c The science of MOTS-c translates into a range of compelling, albeit largely preclinical, therapeutic applications
Other drugmakers that have been testing potential new obesity pills include Roche Holding AG and Pfizer Inc
Physical activity, sleep quality, and stress management round out the lifestyle factors that influence how well GLP-1 supplements perform
Overexpression of phospholipid-hydroperoxide glutathione peroxidase in human dermal fibroblasts abrogates UVA irradiation-induced expression of interstitial collagenase/matrix metalloproteinase-1 by suppression of phosphatidylcholine hydroperoxide-mediated NFkappaB activation and interleukin-6 release
Additionally, a meta-analysis of 26 trials concluded that GLP-1RAs were particularly effective in reducing macrovascular and microvascular complications, positioning them as a strong therapeutic choice for patients at risk of cardiovascular and cerebrovascular disease
Novel anti-diabetic medications designed to treat T2DM, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is), exert beneficial effects on metabolism and the cardiovascular system